Altamira Therapeutics Statistics Share Statistics Altamira Therapeutics has 3.78M
shares outstanding. The number of shares has increased by 68.67%
in one year.
Shares Outstanding 3.78M Shares Change (YoY) 68.67% Shares Change (QoQ) 0% Owned by Institutions (%) 3.13% Shares Floating 2.65M Failed to Deliver (FTD) Shares 7,891 FTD / Avg. Volume 5.59%
Short Selling Information Short Interest n/a Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) n/a
Valuation Ratios The PE ratio is -0.2 and the forward
PE ratio is null.
Altamira Therapeutics's PEG ratio is
0.
PE Ratio -0.2 Forward PE n/a PS Ratio 0 Forward PS 0.2 PB Ratio 0.22 P/FCF Ratio -0.12 PEG Ratio 0
Financial Ratio History Enterprise Valuation Altamira Therapeutics has an Enterprise Value (EV) of 918.84K.
EV / Sales 0 EV / EBITDA -0.68 EV / EBIT -0.08 EV / FCF -0.08
Financial Position The company has a current ratio of 1.38,
with a Debt / Equity ratio of 0.02.
Current Ratio 1.38 Quick Ratio 1.38 Debt / Equity 0.02 Debt / EBITDA -0.07 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is -112.56% and Return on Invested Capital is -85.68%.
Return on Equity -112.56% Return on Assets -94.49% Return on Invested Capital -85.68% Revenue Per Employee n/a Profits Per Employee $-727K Employee Count 10 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -79.17% in the
last 52 weeks. The beta is 2.44, so Altamira Therapeutics's
price volatility has been higher than the market average.
Beta 2.44 52-Week Price Change -79.17% 50-Day Moving Average 0.23 200-Day Moving Average 0.81 Relative Strength Index (RSI) 46.38 Average Volume (20 Days) 141,045
Income Statement
Revenue n/a Gross Profit n/a Operating Income -5.92M Net Income -7.27M EBITDA -1.35M EBIT n/a Earnings Per Share (EPS) -14.81
Full Income Statement Balance Sheet The company has 617.41K in cash and 99.66K in
debt, giving a net cash position of 517.75K.
Cash & Cash Equivalents 617.41K Total Debt 99.66K Net Cash 517.75K Retained Earnings -18.05M Total Assets 7.69M Working Capital 334.24K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -11.51M
and capital expenditures 0, giving a free cash flow of -11.51M.
Operating Cash Flow -11.51M Capital Expenditures n/a Free Cash Flow -11.51M FCF Per Share -23.44
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CYTO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield -506.06% FCF Yield -801.28%
Dividend Details Analyst Forecast Currently there are no analyst rating for CYTO.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 13, 2023. It was a
backward
split with a ratio of 1:20.
Last Split Date Dec 13, 2023 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -3.85 Piotroski F-Score 3
